

**Listing of Claims:**

1. (Currently Amended) An immediate-release pharmaceutical or nutraceutical micronized powder having a particle size of at most 100  $\mu$ m and comprising: a combination of

(a) at least one active substance; ;

(b) at least one wetting agent; and

(c) at least one diluent; and

(d) an antistatic agent comprising from 0.01 % to 10% by weight of the total weight of the composition;

wherein the powder has a dissolution kinetic of less than 30 seconds in an aqueous medium at pH 5 to 9.

2. (Currently Amended) A Powder according to Claim 1, characterized in that it has with a particle size of at most 50 $\mu$ m.

3. (Currently Amended) A Powder according to Claim 1, characterized in that it has with a particle size of at most 10 $\mu$ m.

4. (Currently Amended) A Powder according to Claim 1, characterized in that it allows the dissolution of wherein the powder releases all of the active substance(s) in less than 30 seconds, when it is administered mucosally after mucosal administration.

5. (Currently Amended) A Powder according to Claim 1, characterized in that wherein the active substance is in a micronized form.

6. (Currently amended) A Powder according to Claim 1, wherein the active substance is at least one member selected from the group consisting of cyproterone acetate, norethisterone acetate, progesterone, 3-keto-desogestrel, norgestimate, laevonorgestrel, desogestrel, gestodene, a natural estrogen, a synthetic estrogen,  $\Delta$ -4-androstenedione,

testosterone, dihydrotestosterone, androstanolone, DHEA, trinitrine, fentanyl, nitroglycerine, nicotine (~~nicotine S(-)~~), scopolamine, clonidine, isosorbide dinitrate, alclometasone dipropionate, phloroglucinol, molsidomine, acetazolamide, acyclovir, adapalene, alclomethasone dipropionate, amcinonide, ameline, bamethan sulphate + in combination with escin, betamethasone valerate, betamethasone dipropionate, bufexamac, caffeine, calcipotriol monohydrate, cetrimonium bromide, clobetasol propionate, crilanomer, desonide, dexpanthenol, diclofenac, difluocortolone, valerate, difluprednate, diphenhydramine hydrochloride, econazole nitrate, erythromycin, flumetasone pivalate, fluocinolone acetonide, fluocinodine, fluocortolone, fluocortolone hexanoate, fluocortolone pivalate, hydrocortisone, hydrocortisone acetate, ibacitabine, ibuprofen, imiquimod, ketoconazole, ketoprofen, lidocaine, metronidazole, miconazole nitrate, minoxidil, niflumonic acid, penciclovir, benzoyl peroxide, piroxam, iodinated povidone, promestriene, pyrazinobutazone, roxithromycin, sulphacetamide, triamcinolone, tazarotene, tretinoin and isotretinoin, triclocarban, vidarabine monophosphate,  $\beta$ -3-adrenergic agonist, growth hormone, oxybutinin, buprenorphine, pergolide, nestorone, 7 $\alpha$ - methyl-19-nortesterone, mecamlamine, salbutamol, clenbuterol, selegiline, buspirone, ketotifen, lidocaine, ketorolac, eptazocine, insulin,  $\alpha$ -interferon, prostaglandins, 5-aminolevulinic acid, benzodiazepine alprozolam, diclofenac, fenoprofen, flubiprofen, ketoprofen, methyl phenidate, miconazole, piroxicam, bruprenorphine, alprozolam, dexmedetomidine, prazosin ( ~~$\alpha$ -adrenergic antagonist~~), alprostadil, tulobuterol ( ~~$\alpha$ -adrenergic agonist~~), ethinyl oestradiol + in combination with norelgestromin, ketorolac, physostigmine, medindolol ( ~~$\beta$ -adrenergic agonist~~), rotigotine (~~dopamine D2 antagonist~~), thiatolserine, ~~Esomeprazole~~ esomeprazole, ~~Melagatran~~ melagatran (~~in the case of~~ thrombosis), ~~Rosuvastatin~~ rosuvastatin, ~~Ezetimide~~ ezetimide, ~~Pitavastatin~~ pitavastatin (~~hyperlipidaemia~~), ~~Mitiglinide~~ mitiglinide (~~type II diabetes~~), ~~Cilomilast~~ cilomilast, ~~Viozan~~ viozan (~~asthma~~), ~~Aripipazole~~ aripipazole (~~psychiatry~~), ~~Omapatrilat~~ omapatrilat (~~hypertensive~~), ~~Orzel~~ orzel (~~cancerology~~), ~~Caspofongin~~ caspofongin acetate, ~~Voriconazole~~ voriconazole (~~infections~~), ~~a new COX inhibitor etoricoxib~~, ~~Valdecoxib~~ valdecoxib (~~arthritis~~), ~~and Parecoxib~~ parecoxib, ~~Substance~~ substance P antagonist (~~depression~~), ~~Darifenacin~~ darifenacin (~~urology~~), ~~Eletriptan~~ eletriptan (~~migraine~~), ~~Alosetron~~ alosetron, ~~Tegaserod~~

tegaserod, Capravirine capravirine (HIV), Finasteride finasteride (5-alpha-reductase-inhibitor) and combinations thereof.

7. (Currently Amended) A Ppowder according to Cclaim 1, wherein the active substance is at least one member selected from the group consisting of a vitamin, ~~an~~, ~~inorganic salts, and brewer's yeast, and a mineral salt that is approved for human consumption.~~

8. (Currently Amended) A Ppowder according to Cclaim 1, wherein the wetting agent is at lease one member selected from the group consisting of a polyol, triacetin, a hydrogenated vegetable oil, a polyoxy(ethylene)polyoxy(propylene) copolymer and a polyoxyethylene alkyl ether.

9. (Currently Amended) A Ppowder according to Cclaim 1, wherein the diluent is at least one member selected from the group consisting of calcium or sodium carbonate or bicarbonate, sucrose, mannitol, xylitol, sorbitol, lactose, maltotol, glucose, cellulose, a microcrystalline cellulose powder, starch, a starch derivative, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, a dextrate, a dextrin, a dextrose ~~excipient~~, fructose, kaolin, and lactitol.

10. (Canceled)

11. (Currently Amended) A Ppowder according to Cclaim ~~10~~ 1, ~~characterized in that~~ wherein the antistatic agent is selected from the group consisting of colloidal silica, magnesium silicate, talc, calcium silicate and tribasic calcium phosphate, and mixtures thereof.

12. (Currently Amended) A Ppowder according to Cclaim 1, ~~which~~ further comprising ~~comprises~~ a binder which is comprises at least one member selected from the group consisting of acacia, alginic acid, carboxymethyl cellulose sodium, microcrystalline

cellulose, a dextrin, ethyl cellulose, gelatin, glucose, guar gum, hydroxypropyl methyl cellulose, methyl cellulose, polyethylene oxide, povidone, and pregelatinized starch.

13. (Currently Amended) A Ppowder according to Cclaim 1, ~~which~~ further comprising ~~comprises~~ an absorption enhancer which comprises at least one member selected from the group consisting of an aliphatic fatty acid ester, a fatty acid, an alcohol or polyol, a component of an essential oil, a terpene derivative, a surfactant, a moisturizer, a keratolytic agent, 23-lauryl ether, aprotinin, azone, benzalkonium chloride, cetylpyridinium chloride, cetyltrimethylammonium bromide, a cyclodextrin, dextran sulphate, lauric acid, lysophosphatidylcholine, a menthol, methoxysalicylate, methyl oleate, oleic acid, phosphatidylcholine, polyoxyethylene, polysorbate 80, sodium EDTA, sodium glycocholate, sodium glycodeoxycholate, sodium lauryl sulphate, sodium salicylate, sodium taurocholate, sodium taurodeoxycholate, a sulphoxide, and an alkyl glycoside.

14. (Currently Amended) A Ppowder according to Cclaim 1, ~~characterized in that~~ it further comprising ~~comprises~~ an edulcorant agent and/or a flavoring agent.

15. (Currently Amended) A Ppowder according to Cclaim 14, ~~characterized in that~~ wherein the edulcorant agent is selected from the group consisting of aspartam, dextrans, dextrose, fructose, mannitol, sodium or calcium saccharinate, sorbitol, sucralose, sucrose, and mixtures thereof.

16. (Currently Amended) A Ppowder according to Cclaim 14, wherein the flavoring agent is at least one member selected from the group consisting of a flavor of synthetic, semi-synthetic, or natural origin.

17. (Currently Amended) A Ppowder according to Cclaim 1, ~~characterized in that~~ ~~it is~~ in a form suitable for its application on the buccal mucosa, the nasal mucosa, or the vaginal mucosa.

18. (Currently Amended) A Powder according to Claim 1, ~~characterized in that it is~~ in a form suitable for its sublingual application to the buccal mucosa ~~sublingually~~.

19. (Currently Amended) A Powder according to Claim 1, ~~characterized in that it is~~ in a sprayable form.

20. (Currently Amended) A Powder according to Claim 1, ~~characterized in that it is~~ packaged in a single-dose packet.

21. (Currently Amended) A Powder according to Claim 1, ~~characterized in that it is~~ packaged in a thermally moulded capsule provided with a peelable operculum.

22. (Currently Amended) A Powder according to Claim 1, ~~characterized in that it is~~ provided in a packaging suitable for ~~powder~~ administration of a powder known to those skilled in the art.

23. (Canceled).

24. (Currently Amended) A Powder according to claim 6, wherein the active substance is at least one member selected from the group consisting of estradiol, a natural estradiol derivative, ethinylestradiol, and ~~Etoricoxib~~ etoricoxib (inflammation).

25. (Currently Amended) A Powder according to claim 8, wherein the wetting agent is at least one member selected from the group consisting of PEG, hexylene glycol, triacetin, and a hydrogenated vegetable oil.

26. (Currently Amended) A Powder according to claim 13, wherein the absorption enhancer is at least one member selected from the group consisting of isopropylmyristate, oleic acid, ethanol, propylene glycol, polyethylene glycol, eugenol, geraniol, nerol, eucalyptol, menthol, polyoxyethylene sorbitan, polyoxyethylene alkyl ether, polyoxyethylene derived from castor oil, glycerin, urea, and an alpha-hydroxy acid.

27. (Currently Amended) A method for manufacturing an immediate-release pharmaceutical or nutraceutical composition, ~~said method comprising a step of~~ micronizing a composition comprising: ~~a combination of~~

(a) at least one active substance;

(b) at least one wetting agent; and

(c) at least one diluent; and

(d) an antistatic agent comprising from 0.01 % to 10% by weight of the total weight of the composition.